Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 3/20 | 0.43 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.38 |
| ▸ | FGF1 | P05230 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360431 | 0.84 | FGF1 (0.32) | OGAFGF1CA2CA9CA1 | |
| SCHEMBL25344927 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL30180561 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL24917500 | 0.82 | LMNA (0.37) | — | |
| SCHEMBL22529151 | 0.80 | OGA (0.53) | OGALGALS8PTPN1 | |
| SCHEMBL22542460 | 0.80 | OGA (0.53) | OGALGALS8PTPN1 | |
| SCHEMBL21001779 | 0.80 | OGA (0.53) | OGALGALS8PTPN1 | |
| SCHEMBL2741356 | 0.80 | OGA (0.53) | OGALGALS8PTPN1 | |
| SCHEMBL25866953 | 0.79 | OGA (0.46) | OGALGALS8FGF1CA2CA9 | |
| SCHEMBL25871496 | 0.79 | OGA (0.46) | OGALGALS8FGF1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7230096-B2 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2007-06-12 | — | — | US | disclosed |
| US-20040147730-A1 | Inhibitors against galectins | FORSKARPATENT I SYD AB (SE) | 2004-07-29 | — | — | US | disclosed |
| EP-1353934-A1 | NEW INHIBITORS AGAINST GALECTINS | Nilsson, Ulf (SE) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002057284-A1 | NEW INHIBITORS AGAINST GALECTINS | NILSSON ULF (SE) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147730-A1 | Inhibitors against galectins | LGALS1, LGALS3, LGALS2 | OGA 200/4885LGALS8 6/4885FGF1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.